Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines

Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Last updated: August 22, 2019 Project Number (...) : RA1059-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for varying treatment duration and courses of bisphosphonates for osteoporosis? What are the evidence-based guidelines regarding length of treatment with bisphosphonates for osteoporosis? Key Message One health technology assessment, six systematic reviews (one with meta-analyses), three randomized controlled trials, and five non-randomized studies were identified

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women

Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women | CADTH.ca Find the information you need Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women Last updated: October 11, 2019 Project Number: HE0023-000 Product Line: Technology Review Research Type: Drug Result type: Report Expected (...) Completion Date: December 20, 2019 Osteoporosis is a systemic skeletal disease characterized by a loss of bone mass and an increased risk of fragility fractures. Osteoporosis is highly prevalent, affecting an estimated 1.5 million Canadians over 40 years of age. Fractures associated with osteoporosis commonly occur in vertebral sites, but also occur in non-vertebral sites. They are associated with significant costs, diminished quality of life, and mortality, as well as an increased risk of future

2019 Publication 4890897

3. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01696 Journal of Clinical Oncology - published online before print September 18, 2019 PMID: Management (...) of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline , MD 1 x Charles L. Shapiro ; , MD 2 x Catherine Van Poznak ; , MHSc 3 x Christina Lacchetti ; , MD 4 x Jeffrey Kirshner ; , MD 5 x Richard Eastell ; , MD 6 x Robert Gagel ; , MD 2 x Sean Smith ; , MD, MPH 7 x Beatrice J. Edwards ; , EdM 8 x Elizabeth Frank ; , MD, MPH 9 x Gary H. Lyman ; , MD, PhD 10 x Matthew R. Smith ; , PhD, MPH 11 x Rahul Mhaskar ; , MD, MPH 12 x Tara Henderson ; and , MD, MPH 13 x

2019 American Society of Clinical Oncology Guidelines

4. Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis

Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates: A Meta-analysis Previous studies have reported that drug treatments, particularly treatment with bisphosphonates, is associated with reduced overall mortality rates in addition to decreased fracture risk. If so, drug treatments should be recommended for this reason alone, regardless of a patient's risk of fracture.To assess whether randomized clinical trials demonstrate that treatment (...) with bisphosphonates, particularly zoledronate, is associated with reduced mortality rates.Science Direct, MEDLINE, Embase, and the Cochrane Library were searched for randomized placebo-controlled clinical trials of drug treatments for osteoporosis published after 2009 and published or in press before April 19, 2019. Conference abstracts from annual osteoporosis society meetings were also included in the search.Included studies were clinical trials that (1) were randomized and placebo-controlled; (2) studied drug

2019 EvidenceUpdates

5. Pharmacological Management of Osteoporosis in Postmenopausal Women

Pharmacological Management of Osteoporosis in Postmenopausal Women We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic Search Account Menu Menu Navbar Search Filter Mobile Microsite (...) Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation May 2019 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline Richard Eastell University of Sheffield, Sheffield, United Kingdom Search for other works by this author on: Clifford J Rosen Maine Medical Center Research Institute, Scarborough, Maine Correspondence: Clifford J. Rosen, MD

2019 The Endocrine Society

6. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism

2019 Clinical Correlations

7. Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review

Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Comparative Effectiveness Review Number 218 RComparative Effectiveness Review Number 218 Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 (...) . Timothy J. Wilt, M.D., M.P.H. AHRQ Publication No. 19-EHC016-EF April 2019 ii Key Messages Purpose of Review To summarize the effects of long-term osteoporosis drug treatment and of osteoporosis drug treatment discontinuation and holidays. Key Messages • Evidence on the effects of long-term osteoporosis drug treatment and drug continuation versus discontinuation is mostly limited to white, healthy, postmenopausal women. • Long-term alendronate reduces radiographic vertebral and nonvertebral fractures

2019 Effective Health Care Program (AHRQ)

8. Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture

Romosozumab aqqg (Evenity) - To treat osteoporosis in postmenopausal women at high risk of fracture Drug Approval Package: Evenity U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Evenity Company: Amgen Inc. Application Number: 761062 Approval Date: 04/09/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF

2019 FDA - Drug Approval Package

9. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. (PubMed)

Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review. Optimal long-term osteoporosis drug treatment (ODT) is uncertain.To summarize the effects of long-term ODT and ODT discontinuation and holidays.Electronic bibliographic databases (January 1995 to October 2018) and systematic review bibliographies.48 studies that enrolled men or postmenopausal women aged 50 years or older who were being investigated or treated for fracture (...) prevention, compared long-term ODT (>3 years) versus control or ODT continuation versus discontinuation, reported incident fractures (for trials) or harms (for trials and observational studies), and had low or medium risk of bias (ROB).Two reviewers independently rated ROB and strength of evidence (SOE). One extracted data; another verified accuracy.Thirty-five trials (9 unique studies) and 13 observational studies (11 unique studies) had low or medium ROB. In women with osteoporosis, 4 years

Full Text available with Trip Pro

2019 Annals of Internal Medicine

10. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Common osteoporosis drugs may prevent breast cancer spreading to bone Discover Portal Discover Portal Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 doi: Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However, the overall benefits may

2019 NIHR Dissemination Centre

11. Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain

Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Discover Portal Discover Portal Cement injections to treat spinal compression fractures from osteoporosis can reduce short term pain Published on 13 December 2016 doi: Injecting cement into osteoporotic spinal fractures within six weeks reduces pain in the first few months and disability six (...) centres. Share your views on the research. Why was this study needed? Worldwide, an estimated 1.4 million people with osteoporosis experience vertebral fractures. Most osteoporotic vertebral fractures are treated conservatively with painkillers, bed rest and mobility exercises as function improves. However, painkillers and prolonged bed rest can both have adverse effects in older people. Vertebroplasty involves injecting special cement into the broken vertebrae to relieve pain and strengthen the bone

2019 NIHR Dissemination Centre

12. Prompts for GPs may improve diagnosis and treatment of osteoporosis

Prompts for GPs may improve diagnosis and treatment of osteoporosis Prompts for GPs may improve diagnosis and treatment of osteoporosis Discover Portal Discover Portal Prompts for GPs may improve diagnosis and treatment of osteoporosis Published on 30 August 2016 doi: Prompts for GPs with education and reminders for patients may improve “guideline consistent behaviour” and diagnosis and treatment of osteoporosis. Similar techniques aimed at improving GP management of other common (...) benefit more. Share your views on the research. Why was this study needed? Musculoskeletal conditions such as osteoporosis, back pain and arthritis are common causes of pain and disability in the UK. One in six adults lives with a chronic musculoskeletal condition. Every year, over 20% of people consult their GP about musculoskeletal problems. Musculoskeletal conditions are a major cause of health system spending. In 2009-10, the NHS spent £4.76 billion in this area; this is more than £13 million

2019 NIHR Dissemination Centre

13. Osteoporosis. (PubMed)

Osteoporosis. Fractures resulting from osteoporosis become increasingly common in women after age 55 years and men after age 65 years, resulting in substantial bone-associated morbidities, and increased mortality and health-care costs. Research advances have led to a more accurate assessment of fracture risk and have increased the range of therapeutic options available to prevent fractures. Fracture risk algorithms that combine clinical risk factors and bone mineral density are now widely used (...) in clinical practice to target high-risk individuals for treatment. The discovery of key pathways regulating bone resorption and formation has identified new approaches to treatment with distinctive mechanisms of action. Osteoporosis is a chronic condition and long-term, sometimes lifelong, management is required. In individuals at high risk of fracture, the benefit versus risk profile is likely to be favourable for up to 10 years of treatment with bisphosphonates or denosumab. In people at a very high

2019 Lancet

14. The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper

The Prevention of glucocorticoid?induced osteoporosis in patients with immune thrombocytopenia receiving steroids: Good Practice Paper The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper - Hill - - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term (...) The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access The prevention of glucocorticoid‐induced osteoporosis in patients with immune thrombocytopenia receiving steroids: a British Society for Haematology Good Practice Paper Department of Haematology, Leeds Teaching Hospitals, Leeds, UK Royal Manchester Children's Hospital, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK Faculty

Full Text available with Trip Pro

2019 British Committee for Standards in Haematology

15. A systemic review and network meta-analysis of the efficacy and safety of bisphosphonates and RANKL inhibitors for the treatment of glucocorticoid-induced osteoporosis

A systemic review and network meta-analysis of the efficacy and safety of bisphosphonates and RANKL inhibitors for the treatment of glucocorticoid-induced osteoporosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

16. The methodological quality of guideline recommendations on vitamin D and calcium intakes: a systematic review of food-based dietary guidelines and osteoporosis prevention guidelines

The methodological quality of guideline recommendations on vitamin D and calcium intakes: a systematic review of food-based dietary guidelines and osteoporosis prevention guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

17. The efficacy and safety of isoflavone treatment in post-menopausal women with osteoporosis: a systematic review and meta-analysis

The efficacy and safety of isoflavone treatment in post-menopausal women with osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

18. Romosozumab for the treatment of osteoporosis: a systematic review and meta-analysis

Romosozumab for the treatment of osteoporosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

19. Association between osteoporosis/osteopenia and multiple sclerosis: a meta-analysis

Association between osteoporosis/osteopenia and multiple sclerosis: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

20. Acupoint injection treatment for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Acupoint injection treatment for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO